Clinical Trials
6
Active:0
Completed:1
Trial Phases
3 Phases
Phase 1:4
Phase 2:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (66.7%)Not Applicable
1 (16.7%)Phase 2
1 (16.7%)A Phase 2 Study to Evaluate the Safety and Efficacy of BEY2153 in Patients with Early Alzheimer's Disease
Phase 2
Not yet recruiting
- Conditions
- Alzheimer DiseaseAlzheimer' Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-03-20
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- BeyondBio Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06885567
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
🇰🇷SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of
🇰🇷Yeouido St. Mary's Hospital, Seoul, Korea, Republic of
A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)
Phase 1
Recruiting
- Conditions
- Glioblastoma Multiforme
- Interventions
- Combination Product: Temozolomide
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- BeyondBio Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05769660
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer
Phase 1
Recruiting
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Combination Product: Capecitabine
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- BeyondBio Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT05093907
- Locations
- 🇰🇷
Seoul National University Hospial, Seoul, Jongro-go, Korea, Republic of
A Study to Evaluate the Pharmacokinetics and Safety of BEY2153 in Healthy Participants
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- BeyondBio Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT04476303
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer
Phase 1
Recruiting
- Conditions
- Locally Advanced or Metastatic Pancreatic Cancer
- Interventions
- Combination Product: Gemcitabine
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- BeyondBio Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT03579836
- Locations
- 🇰🇷
Yonsei University Health System Severance Hospital, Seoul, Korea, Republic of
News
No news found